Table 3.

Association of plasma phospholipid fatty acids with ovarian cancer risk in the EPIC cohort.

Tertile 1Tertile 2Tertile 3
Plasma phospholipid fatty acids (% of total fatty acids)ReferenceOR (95% CI)OR (95% CI)Ptrenda
Total SFAb
 Mean ± SD39.58 ± 1.2740.91 ± 0.2542.20 ± 0.94
 Cases/controls (n)233/418185/416215/414
 OR (95% CI)c1.000.82 (0.64–1.06)0.93 (0.70–1.23)0.57
Palmitic acid (16:0)
 Mean ± SD24.08 ± 1.5725.88 ± 0.4227.90 ± 1.12
 Cases/controls (n)222/419224/418187/411
 OR (95% CI)c1.000.94 (0.73–1.21)0.81 (0.59–1.09)0.17
Total cis MUFAd
 Mean ± SD10.84 ± 0.9312.76 ± 0.4415.16 ± 1.55
 Cases/controls (n)214/418207/416212/414
 OR (95% CI)c1.000.96 (0.75–1.23)0.94 (0.72–1.22)0.63
Oleic acid (18:1n-9)
 Mean ± SD8.44 ± 0.7710.08 ± 0.3912.33 ± 1.49
 Cases/controls (n)218/417187/415228/416
 OR (95% CI)c1.000.85 (0.66–1.09)0.99 (0.76–1.30)0.95
Total rTFAe
 Mean ± SD0.26 ± 0.060.41 ± 0.040.62 ± 0.15
 Cases/controls (n)233/456173/389227/403
 OR (95% CI)c1.000.91 (0.67–1.22)1.14 (0.81–1.61)0.40
Total iTFAf
 Mean ± SD0.44 ± 0.060.62 ± 0.050.98 ± 0.48
 Cases/controls (n)214/447199/387220/414
 OR (95% CI)c1.001.11 (0.83–1.48)1.15 (0.82–1.64)0.40
Elaidic acid (18:1n-9/12)
 Mean ± SD0.14 ± 0.030.24 ± 0.040.55 ± 0.19
 Cases/controls (n)196/419211/425226/404
 OR (95% CI)c1.001.12 (0.86–1.47)1.39 (0.99–1.94)0.06
Total cis n-6 PUFAg
 Mean ± SD34.08 ± 2.3937.74 ± 0.6440.91 ± 1.66
 Cases/controls (n)214/417195/415224/416
 OR (95% CI)c1.000.93 (0.71–1.19)1.08 (0.84–1.41)0.49
Linoleic acid (18:2n-6)
 Mean ± SD18.72 ± 1.9822.38 ± 0.7926.10 ± 1.92
 Cases/controls (n)197/418218/414218/416
 OR (95% CI)c1.001.20 (0.93–1.54)1.17 (0.90–1.52)0.23
Long-chain n-6 PUFAh
 Mean ± SD12.40 ± 1.6115.05 ± 0.5517.68 ± 1.43
 Cases/controls (n)221/416195/418217/414
 OR (95% CI)c1.000.83 (0.64–1.08)0.98 (0.74–1.28)0.85
Total cis n-3 PUFAi
 Mean ± SD5.26 ± 0.686.98 ± 0.479.92 ± 2.19
 Cases/controls (n)230/426216/408187/414
 OR (95% CI)c1.000.91 (0.71–1.16)0.78 (0.59–1.04)0.09
α-linolenic acid (18:3n-3ccc)
 Mean ± SD0.12 ± 0.020.18 ± 0.020.28 ± 0.07
 Cases/controls (n)226/473169/365238/410
 OR (95% CI)c1.001.01 (0.76–1.32)1.30 (0.98–1.72)0.06
Long chain n-3 PUFAj
 Mean ± SD5.06 ± 0.676.76 ± 0.489.71 ± 2.19
 Cases/controls (n)222/417223/415188/416
 OR (95% CI)c1.000.93 (0.73–1.20)0.80 (0.61–1.06)0.13
Total cis PUFAk
 Mean ± SD42.35 ± 1.7445.06 ± 0.5347.38 ± 1.34
 Cases/controls (n)218/416208/416207/416
 OR (95% CI)c1.000.97 (0.75–1.26)0.95 (0.73–1.24)0.73
Ratio n-6/n-3 PUFA
 Mean ± SD3.69 ± 0.785.47 ± 0.447.78 ± 1.54
 Cases/controls (n)195/418216/414222/416
 OR (95% CI)c1.001.12 (0.87–1.45)1.21 (0.91–1.60)0.19
DI16 (16:1n-7/n-9/16:0)
 Cases/controls (n)399/793180/37852/77
 OR (95% CI)c1.000.94 (0.74–1.19)1.22 (0.18–1.84)0.70
DI18 (18:1n-9/18:0)
 Cases/controls (n)214/421216/432203/395
 OR (95% CI)c1.000.99 (0.77–1.28)0.95 (0.72–1.25)0.71
  • Abbreviation: DI, desaturation index.

  • aP values < 0.05 are shown in boldface.

  • bTotal SFA included 12:0, 14:0, 15:0, 16:0, 17:0, 18:0, 20:0, 22:0, 24:0.

  • cCases and controls (1:2) are matched for study center, menopausal status, age, fasting status, and time of the day at blood collection, and adjusted for duration of oral contraceptive use, parity, menopausal status, and total energy intake.

  • dTotal cis MUFA included 14:1, 15:1, 16:1n-7/n-9, 17:1, 18:1n-5, 18:1n-7, 18:1n-9, 20:1, 22:1, 24:1.

  • eTotal rTFA included 18:1n-7t, CLA.

  • fTotal iTFA included 16:1n-7t/n-9t, 18:1n-12/n-9t, 18:2n-6tt, 18:2n-6tc, 18:3n-3ttt.

  • gTotal n-6 PUFA included 18:2, 18:3, 20:2, 20:3, 20:4, 22:4, 22:5.

  • hTotal long-chain n-6 PUFA included 20:2, 20:3, 20:4, 22:4, 22:5.

  • iTotal n-3 PUFA included 18:3, 18:4, 20:4, 20:5, 22:5, 22:6.

  • jTotal long-chain n-3 PUFA included 20:4, 20:5, 22:5, 22:6.

  • kTotal cis PUFA included total n-6 PUFA and total n-3 PUFA.